Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1962 2
1963 3
1964 15
1965 7
1966 7
1967 30
1968 51
1969 31
1970 39
1971 42
1972 28
1973 20
1974 22
1975 21
1976 13
1977 10
1978 21
1979 14
1980 12
1981 6
1982 13
1983 13
1984 20
1985 10
1986 31
1987 16
1988 12
1989 32
1990 19
1991 51
1992 63
1993 69
1994 75
1995 100
1996 96
1997 121
1998 142
1999 211
2000 355
2001 565
2002 712
2003 839
2004 940
2005 1005
2006 1069
2007 1160
2008 1319
2009 1268
2010 1389
2011 1464
2012 1615
2013 1664
2014 1952
2015 2058
2016 2233
2017 2320
2018 2250
2019 2273
2020 2395
2021 1806
Text availability
Article attribute
Article type
Publication date

Search Results

30,618 results
Results by year
Filters applied: . Clear all
Page 1
Pharmacogenomics: Prescribing Precisely.
Wake DT, Ilbawi N, Dunnenberger HM, Hulick PJ. Wake DT, et al. Med Clin North Am. 2019 Nov;103(6):977-990. doi: 10.1016/j.mcna.2019.07.002. Epub 2019 Aug 24. Med Clin North Am. 2019. PMID: 31582008 Review.
Pharmacogenomics (PGx) is a powerful tool that can predict increased risks of adverse effects and sub-therapeutic response to medications. ...
Pharmacogenomics (PGx) is a powerful tool that can predict increased risks of adverse effects and sub-therapeutic response to medicat
Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer.
Morganti S, Tarantino P, Ferraro E, D'Amico P, Duso BA, Curigliano G. Morganti S, et al. Adv Exp Med Biol. 2019;1168:9-30. doi: 10.1007/978-3-030-24100-1_2. Adv Exp Med Biol. 2019. PMID: 31713162 Review.
In this chapter we discuss the history, available techniques and applications of NGS in oncology, with a particular referral to the PM approach and the emerging role of the research field of pharmacogenomics....
In this chapter we discuss the history, available techniques and applications of NGS in oncology, with a particular referral to the PM appro …
Warfarin Pharmacogenomics in Diverse Populations.
Kaye JB, Schultz LE, Steiner HE, Kittles RA, Cavallari LH, Karnes JH. Kaye JB, et al. Pharmacotherapy. 2017 Sep;37(9):1150-1163. doi: 10.1002/phar.1982. Epub 2017 Sep 6. Pharmacotherapy. 2017. PMID: 28672100 Free PMC article. Review.
Careful consideration of race/ethnicity and additional evidence focused on improving warfarin dosing algorithms across race/ethnic groups will be necessary for successful clinical implementation of warfarin pharmacogenomics. The evidence for warfarin pharmacogenomics
Careful consideration of race/ethnicity and additional evidence focused on improving warfarin dosing algorithms across race/ethnic groups wi …
Considerations When Applying Pharmacogenomics to Your Practice.
Nicholson WT, Formea CM, Matey ET, Wright JA, Giri J, Moyer AM. Nicholson WT, et al. Mayo Clin Proc. 2021 Jan;96(1):218-230. doi: 10.1016/j.mayocp.2020.03.011. Epub 2020 Dec 9. Mayo Clin Proc. 2021. PMID: 33308868 Review.
Many practitioners who have not had pharmacogenomic education are required to apply pharmacogenomics to their practices. ...We searched PubMed with the search terms pharmacogenomics and pharmacogenetics (January 1, 2005, through December 31, 2019) and …
Many practitioners who have not had pharmacogenomic education are required to apply pharmacogenomics to their practices. ...We …
Pharmacogenomics of autism spectrum disorder.
Brown JT, Eum S, Cook EH, Bishop JR. Brown JT, et al. Pharmacogenomics. 2017 Mar;18(4):403-414. doi: 10.2217/pgs-2016-0167. Epub 2017 Feb 22. Pharmacogenomics. 2017. PMID: 28244813 Review.
The majority of pharmacogenomic studies to date have focused on antipsychotics, antidepressants and stimulants that are the most commonly utilized medication classes for ASD. This review is a comprehensive examination of the existing pharmacogenomic studies in ASD h …
The majority of pharmacogenomic studies to date have focused on antipsychotics, antidepressants and stimulants that are the most comm …
Pharmacogenomics and Personalized Medicine.
Cecchin E, Stocco G. Cecchin E, et al. Genes (Basel). 2020 Jun 22;11(6):679. doi: 10.3390/genes11060679. Genes (Basel). 2020. PMID: 32580376 Free PMC article.
Many coordinated international efforts are ongoing in order to overcome the existing barriers to pharmacogenomic implementation. On the other hand, existing validated pharmacogenomic markers can explain only a minor part of the observed clinical variability in the t …
Many coordinated international efforts are ongoing in order to overcome the existing barriers to pharmacogenomic implementation. On t …
Pharmacogenomics guidelines: Current status and future development.
Guo C, Xie X, Li J, Huang L, Chen S, Li X, Yi X, Wu Q, Yang G, Zhou H, Liu JP, Chen X. Guo C, et al. Clin Exp Pharmacol Physiol. 2019 Aug;46(8):689-693. doi: 10.1111/1440-1681.13097. Epub 2019 May 16. Clin Exp Pharmacol Physiol. 2019. PMID: 31009088 Review.
Genetic polymorphisms impact biological responses to drugs. Current pharmacogenomics guidelines formulated by different countries, such as the Clinical Pharmacogenetics Implementation Consortium, the Dutch Pharmacogenetics Working Group, the Canadian Pharm
Genetic polymorphisms impact biological responses to drugs. Current pharmacogenomics guidelines formulated by different countries, su …
Integrating pharmacogenomics into electronic health records with clinical decision support.
Hicks JK, Dunnenberger HM, Gumpper KF, Haidar CE, Hoffman JM. Hicks JK, et al. Am J Health Syst Pharm. 2016 Dec 1;73(23):1967-1976. doi: 10.2146/ajhp160030. Am J Health Syst Pharm. 2016. PMID: 27864204 Free PMC article. Review.
PURPOSE: Existing pharmacogenomic informatics models, key implementation steps, and emerging resources to facilitate the development of pharmacogenomic clinical decision support (CDS) are described. ...Effective integration of pharmacogenomic CDS into the EHR …
PURPOSE: Existing pharmacogenomic informatics models, key implementation steps, and emerging resources to facilitate the development …
Pharmacogenomics and ALL treatment: How to optimize therapy.
Karol SE, Yang JJ. Karol SE, et al. Semin Hematol. 2020 Jul;57(3):130-136. doi: 10.1053/j.seminhematol.2020.10.001. Epub 2020 Oct 20. Semin Hematol. 2020. PMID: 33256902 Review.
In this review, we discuss evidence from children and young adults with acute lymphoblastic leukemia to review the available pharmacogenomic data with an emphasis on clinically actionable and emerging discoveries, for example, genetic variants in thiopurine methyltransfera …
In this review, we discuss evidence from children and young adults with acute lymphoblastic leukemia to review the available pharmacogeno
Pharmacogenomics of Alzheimer's and Parkinson's diseases.
Cacabelos R. Cacabelos R. Neurosci Lett. 2020 May 1;726:133807. doi: 10.1016/j.neulet.2018.09.018. Epub 2018 Sep 17. Neurosci Lett. 2020. PMID: 30236877 Review.
Patients with NDDs currently receive polypharmacy with a high risk for drug-drug interactions and severe adverse drug events. Pharmacogenomics accounts for 60-90% variability in drug pharmacokinetics and pharmacodynamics. Major determinants of the pharmacogenomic ou …
Patients with NDDs currently receive polypharmacy with a high risk for drug-drug interactions and severe adverse drug events. Pharmacogen
30,618 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page